Loading clinical trials...
Loading clinical trials...
A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
Age
12 - 70 years
Sex
ALL
Healthy Volunteers
No
N01235 1007
Curitiba, Brazil
N01235 2001
Kuopio, Finland
N01235 2003
Tampere, Finland
N01235 2002
Turku, Finland
N01235 3008
Chennai, India
N01235 3010
Chennai, India
N01235 3012
Gandhinagar, India
N01235 3003
Hyderabad, India
N01235 3004
Hyderabad, India
N01235 3001
Lucknow, India
Start Date
August 1, 2006
Primary Completion Date
May 1, 2007
Completion Date
May 1, 2007
Last Updated
July 15, 2020
158
ACTUAL participants
Keppra® extended release formulation - XR
DRUG
Placebo
DRUG
Lead Sponsor
UCB Pharma
NCT06700356
NCT02531880
NCT05871372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions